Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in Lymphomas - Episode 3

ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL

,

Loretta J. Nastoupil, MD, reviews data from the ZUMA-7 trial investigating the use of axicabtagene ciloleucel as a second-line therapy for large b-cell lymphoma.

EP. 1: Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
EP. 2: Currently Available Treatment Options for Patients With R/R DLBCL
Now Viewing
EP. 3: ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
EP. 4: Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
EP. 5: Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
EP. 6: Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)
EP. 7: CAR T-Cell Therapy for Patients With R/R FL
EP. 8: Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Related Content:

Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in LymphomasNon-Hodgkin LymphomaCAR T-cell TherapyConferenceOncLive News Network®
Dr Leslie on the 5-Year Follow-Up of the ZUMA-5 Trial in R/R Indolent NHL
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC